CVX-045-101
A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors
Sponsor study identifier
interventional
40
1 country
3
Study Start
February 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2009
Actual (reported)Study Completion
November 2010
Actual (reported)The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2007
Date type not reportedThis date has not been verified as actual or estimated.
March 2009
Actual (reported)April 9, 2009
Actual (reported)April 10, 2009
Actual (reported)November 2010
Actual (reported)To determine safety and tolerability of CVX-045 as weekly intravenous (IV) infusions in adult patients with advanced solid tumors
Throughout duration of study
To identify and characterize CVX-045-related adverse events (AEs)
Throughout duration of study
To evaluate the plasma pharmacokinetics (PK) of CVX-045
Days 1, 4, 8, 15, 29
Weekly, intravenous dose
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Pfizer Investigational Site
Scottsdale, Arizona, 85258, United States
Pfizer Investigational Site
Santa Monica, California, 90404, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19111, United States
Pfizer CT.gov Call Center
Pfizer
40 participants (actual enrollment reported by the registry).
First Submitted
April 9, 2009
First Posted
April 10, 2009
Study Start
February 2007
Date type not reportedThis date has not been verified as actual or estimated.
To determine a recommended Phase 2 dose of CVX-045
End of study
To evaluate the potential for immunogenicity of CVX-045
Days 1, 15, 1st day of every subsequent cycle, EOS, 30 Day FU
To document any preliminary evidence of antitumor activity
Every 8 weeks
Contact the study team to confirm eligibility.
Primary Completion
March 2009
Actual (reported)Study Completion
November 2010
Actual (reported)Last Updated
December 13, 2010
Record last verified: 2010-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: